Abdominal adiposity in HIV-1 patients initiating antiretroviral therapy may be part of a restoration-to-health phenomenon. Lipoatrophy is associated with long-term thymidine analogue therapy. Individual protease inhibitors (PIs) differ in their effects on lipids and insulin resistance.
Methods
A randomized open-label multicentre 96-week trial compared changes in fat distribution in patients with suppressed HIV-1 RNA and abdominal adiposity, who either continued on their current twice-daily ritonavir-boosted PI (PI/r) or switched to once-daily boosted atazanavir (ATV/r). Treatment with two nucleoside reverse transcriptase inhibitors was unchanged. Body composition was assessed by dual-energy x-ray absorptiometry (DEXA) and abdominal computerized tomography (CT) scanning.
Results
In total, 201 patients were randomized; 131 switched to ATV/r. Viral suppression (<50 copies/ml) was similarly maintained (93% ATV/r versus 89% PI/r). Mean changes from baseline in trunk-to-limb fat ratio were similar; difference estimates 0.03 (95% CI -0.06, 0.12; P=0.48 at week 48) and 0.02 (95% CI -0.10, 0.14; P=0.73 at week 96). More patients in the PI/r arm had a decrease of ≥20% in limb fat from baseline at week 96. Significantly greater reductions in proatherogenic lipids occurred following switch to ATV/r. Both treatment regimens were generally well-tolerated; the incidence of grade 3–4 treatment-related clinical adverse events was 34% among ATV/r recipients versus 4% of PI/r-treated patients.
Conclusions
Switching to ATV/r had no demonstrable benefit on abdominal adiposity. Maintenance of efficacy, less limb fat loss and marked reduction in proatherogenic lipids was observed with ATV/r compared with continuing a PI/r regimen.
References
1.
GazzardB.G.British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med2008; 9: 563–608.
2.
HammerS.M., EronJ.J.Jr., ReissP.Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA2008; 300: 555–570.
3.
MulliganK., GrunfeldC., TaiV.W.Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr2000; 23: 35–43.
4.
MallonP.W., MillerJ., CooperD.A.Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS2003; 17: 971–979.
5.
CarrA., SamarasK., BurtonS.A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS1998; 12: F51–F58.
6.
BernasconiE., BoubakerK., JunghansC.Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr2002; 31: 50–55.
7.
BlassS.C., EllingerS., VogelM.Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism – a reason for glycemic control. Eur J Med Res2008; 13: 209–214.
8.
Saint-MarcT., PartisaniM., Poizot-MartinI.A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS1999; 13: 1659–1667.
9.
GrunfeldC., RimlandD., GibertC.L.Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr2007; 46: 283–290.
10.
WohlD., ScherzerR., HeymsfieldS.The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr2008; 48: 44–52.
11.
MynarcikD.C., McNurlanM.A., SteigbigelR.T.Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr2000; 25: 312–321.
12.
CofrancescoJ., FreedlandE., McComseyG.Treatment options for HIV-associated central fat accumulation. AIDS Patient Care STDS2009; 23: 5–18.
13.
MaussS., SchmutzG.[HIV-lipodystrophy syndrome]. Med Klin (Munich)2001; 96: 391–401. German.
14.
FalusiO.M., AbergJ.A.HIV and cardiovascular risk factors. AIDS Read2001; 11: 263–268.
15.
WormS.W., SabinC., WeberR.Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis2010; 201: 318–330.
16.
MillerK.D., JonesE., YanovskiJ.A.Visceral abdominal-fat accumulation associated with use of indinavir. Lancet1998; 351: 871–875.
17.
JohnsonM., GrinsztejnB., RodriguezC.96-Week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS2006; 20: 711–718.
18.
MallolasJ., PodzamczerD., MilinkovicA.Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: The ATAZIP Study. J Acquir Immune Defic Syndr2009; 51: 29–36.
19.
SorianoV., Garcia-GascoP., VispoE.Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother2008; 61: 200–205.
20.
GatellJ., Salmon-CeronD., LazzarinA.Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis2007; 44: 1484–1492.
21.
JacksonA., PatelN., LoG.Effects of atazanavir or saquinavir once daily with ritonavir 100 mg and tenofovir/ emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal: a randomized open-label study.14th Conference on Retroviruses and Opportunistic Infections. 25–28 February 2007, Los Angeles, CA, USA. Abstract 818.
22.
MöbiusU., Lubach-RuitmanM., Castro-FrenzelB.Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr2005; 39: 174–180.
23.
MolinaJ.M., Andrade-VillanuevaJ., EchevarriaJ.Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet2008; 372: 646–655.
24.
BustiA.J., BedimoR., MargolisD.M.Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med2008; 56: 539–544.
25.
NoorM.A., ParkerR.A., O'MaraE.The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS2004; 18: 2137–2144.
26.
NoorM.A., FlintO.P., MaaJ.F.Effects of atazanavir/ ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS2006; 20: 1813–1821.
27.
DubéM.P., ShenC., GreenwaldM., MatherK.No impairment of endothelial function of insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis2008; 47: 567–574.
28.
StanleyT.L., JoyT., HadiganC.M.Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS2009; 23: 1349–1357.
29.
MolariusA., SedellJ.C.Selection of anthropometric indicators for classification of abdominal fatness: a critical review. Int J Obes Relat Metab Disord1998; 22: 719–727.
30.
HaubrichR.H., RiddlerS.A., DiRienzoA.G.Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS2009; 23: 1109–1118.
31.
Third report of the National Cholesterol Education Program (NCEP)Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation2002; 106: 3143–3421.
32.
DesprésJ.P.Health consequences of visceral obesity. Ann Med2001; 33: 534–541.
33.
Collot-TeixeiraS., De LorenzoF., WatersL.Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. Clin Pharmacol Ther2009; 85: 375–378.
34.
AbergJ., OvertonT., GuptaS.METABOLIK (Metabolic Evaluation in Treatment-naives Assessing the impact of two BOosted protease inhibitors on LIpids and other marKers): comparison of the metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir over 12 weeks.18th International AIDS Conference. 18–23 July 2010, Vienna, Austria. Abstract WEPE0111.
35.
SkiestD., CohenC., KhanlouH.Randomized comparison of DRV/r vs ATV/r on serum lipids in HIV-positive persons on fully suppressive LPV/r or FPV/r with high serum triglycerides.18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 817.
36.
MulliganK., ParkerR.A., KomarowL.Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr2006; 41: 590–597.
37.
MoyleG.J., BaldwinC., LangroudiB.A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr2003; 33: 22–28.
38.
MoyleG., BaldwinC., ComitisS.Management of metabolic and body shape changes occurring during protease inhibitor (PI) therapy by substitution of PI with efavirenz in virologically controlled HIV-1 positive persons: a single arm observational cohort. J Acquir Immune Defic Syndr2001; 28: 399–401.
39.
CarrA., WorkmanC., SmithD.E.Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA2002; 288: 207–215.
40.
TebasP., ZhangJ., HafnerR.Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother2009; 63: 998–1005.
41.
MartinA., SmithD.E., CarrA.Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS2004; 18: 1029–1036.
42.
MoyleG.J., SabinC.A., CartledgeJ.RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS2006; 20: 2043–2050.
43.
MatsubaraM., MaruokaS., KatayoseS.Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol2002; 147: 173–180.
44.
YamamotoY., HiroseH., SaitoI.Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond)2002; 103: 137–142.
NoorM.A., LoJ.C., MulliganK.Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS2001; 15: F11–F18.
47.
CarrA.An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet2003; 361: 726–735.
48.
GrunfeldC., ThompsonM., BrownS.J.Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr2007; 45: 286–297.
49.
FalutzJ., AllasS., MamputuJ.C.Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS2008; 22: 1719–1728.
50.
FerranniniE., NataliA., BellP.Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest1997; 100: 1166–1173.
51.
RossR., RissanenJ., HudsonR.Sensitivity associated with the identification of visceral adipose tissue levels using waist circumference in men and women: effects of weight loss. Int J Obes Relat Metab Disord1996; 20: 533–538.
52.
RattarasarnC., LeelawattanaR., SoonthornpunS.Regional abdominal fat distribution in lean and obese Thai type 2 diabetic women: relationships with insulin sensitivity and cardiovascular risk factors. Metabolism2003; 52: 1444–1447.
53.
LovejoyJ.C., De La BretonneJ.A., KlempererM.Abdominal fat distribution and metabolic risk factors: effects of race. Metabolism1996; 45: 1119–1124.
54.
BacchettiP., GripshoverB., GrunfeldC.Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr2005; 40: 121–131.
55.
EvansD.J., MurrayR., KissebahA.H.Relationship between skeletal muscle insulin resistance, insulin mediated glucose disposal, and insulin binding. Effects of obesity and body fat topography. J Clin Invest1984; 74: 1515–1525.
